Option Care Health reported preliminary, unaudited net revenue of $1.46 billion to $1.47 billion for Q4 2025, reflecting an 8.1% increase from $1.35 billion a year earlier. On a GAAP basis, the company expects net income of $59.1 million to $62.4 million and diluted EPS of $0.37 to $0.39. Adjusted EBITDA is projected at $123.7 million to $127.7 million, while non-GAAP net income is estimated at $73.8 million to $79.0 million, or $0.46 to $0.49 per share, compared with $75.5 million in adjusted net profit in Q4 2024.

For the full year ended December 31, 2025, preliminary net revenue is expected between $5.645 billion and $5.655 billion, up from approximately $5.22 billion in 2024. GAAP net income is forecast at $208.2 million to $211.5 million, with diluted EPS of $1.27 to $1.29. Adjusted diluted EPS is seen at $1.72 to $1.76 and adjusted EBITDA at $469.0 million to $473.0 million. Cash flow from operations is anticipated below $320 million.

Option Care Health provided preliminary guidance for fiscal 2026, projecting net revenue of $5.8 billion to $6.0 billion, a year-over-year increase of up to 6.2% at the midpoint. The company expects adjusted diluted EPS of $1.82 to $1.92 and adjusted EBITDA of $480 million to $505 million. Management will offer further detail on its February earnings call.

On January 9, 2026, the board doubled the share repurchase program authorization from $500 million to $1.0 billion with no expiration date. During Q4 2025, the company repurchased $95 million of shares and $307 million during the full year, leaving $193 million in capacity under the original program. The additional $500 million will provide flexibility for open-market and negotiated repurchases, subject to market and regulatory considerations.